Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-6-26
|
pubmed:abstractText |
In the present study we investigated the effectiveness of 14, 15 and 18 nucleotide antisense phosphorothioate oligonucleotides (S-ODNs) directed to four different regions of the published mdr-1 gene sequence to reduce the level of mdr-1 gene product (p170, P-glycoprotein) and its function in the over-expressing cell lines Lo-VoDxR, S180DxR and KBChR8-5. The highest efficiency in reduction of multiple drug resistance was obtained at a concentration of 2 microM. In proliferation assays a growth reduction of 50% was observed after exposure of doxorubicin-resistant cells to S-ODN3. p170 protein expression of the resistant cell line LoVoDxR was reduced to the level of the sensitive cell line LoVo as shown by Western blot analysis. S-ODN3 reduced the ID50 of the two human cell lines up to 60% (LoVoDxR) and 21% (KBChR8-5), respectively, but showed no effect in the murine cell line S180DxR. In contrast, S-ODN1 was most effective in the murine system (67% reduction of the ID50), less effective in LoVoDxR (34%) and exhibited no effect in cell line KBChR8-5. Based on the results with the antisense oligonucleotides, a ribozyme directed against the mRNA target region of S-ODN3 was designed. This ribozyme was able to reduce the mdr-1 mRNA in total RNA preparations from cell line LoVoDxR up to 80% after an incubation time of 6 h in the presence of 10 mM MgCl2 at pH 7.5. A modified ribozyme was investigated in cell culture and reduced chemo-resistance of the resistant cell line LoVoDxR and ex vivo cultured blasts of acute myeloid leukemia patients up to 50%.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Doxorubicin,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Oligonucleotides, Antisense,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Catalytic,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen,
http://linkedlifedata.com/resource/pubmed/chemical/Thionucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/Verapamil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0959-4973
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
6
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
124-34
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7756675-Base Sequence,
pubmed-meshheading:7756675-Cell Division,
pubmed-meshheading:7756675-Doxorubicin,
pubmed-meshheading:7756675-Drug Resistance, Multiple,
pubmed-meshheading:7756675-Genes, Neoplasm,
pubmed-meshheading:7756675-Humans,
pubmed-meshheading:7756675-Molecular Sequence Data,
pubmed-meshheading:7756675-Neoplasm Proteins,
pubmed-meshheading:7756675-Oligonucleotides, Antisense,
pubmed-meshheading:7756675-P-Glycoprotein,
pubmed-meshheading:7756675-RNA, Catalytic,
pubmed-meshheading:7756675-RNA, Messenger,
pubmed-meshheading:7756675-RNA, Neoplasm,
pubmed-meshheading:7756675-Tamoxifen,
pubmed-meshheading:7756675-Thionucleotides,
pubmed-meshheading:7756675-Tumor Cells, Cultured,
pubmed-meshheading:7756675-Verapamil
|
pubmed:year |
1995
|
pubmed:articleTitle |
Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes.
|
pubmed:affiliation |
Department of Hematology/Oncology, University Clinics, Göttingen, Germany.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|